Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22545809 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30543757 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30543772 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL22545721 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL22545814 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL22545813 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL22545803 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL22527573 | 0.81 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL4709679 | 0.79 | PRMT5 (0.64) | PRMT5WDR77 | |
| SCHEMBL313776 | 0.78 | PRMT5 (0.64) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-11485731-B2 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | Argonaut Therapeutics Limited (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485731-B2 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 143/4885 |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.